Skip to main content
Premium Trial:

Request an Annual Quote

IP Roundup: Nanosphere, Canon, Affymetrix, Luminex, Plexera, and Others


Nanosphere of Northbrook, Ill., has received US Patent No. 8,323,888, "Nanoparticles having oligonucleotides attached thereto and uses therefor." The claimed methods include contacting a nucleic acid with particles that have oligonucleotides attached to them. In one embodiment, the oligos are attached to nanoparticles and have sequences complementary to portions of the sequence of the nucleic acid. A detectable change, preferably a color change, is brought about as a result of the hybridization of the oligos on the nanoparticles. The patent also provides methods of synthesizing unique nanoparticle-oligonucleotide conjugates, the conjugates produced by the methods, and methods of using the conjugates.

Canon of Tokyo has received US Patent No. 8,323,892, "Hybridization method and apparatus." According to the patent, a target nucleic acid contained in a sample solution is hybridized with a probe nucleic acid capable of binding specifically to the target nucleic acid and immobilized on a substrate. The process includes hybridizing the target nucleic acid with the probe nucleic acid, collecting the sample solution that has undergone the hybridization, amplifying the target nucleic acid contained in the collected sample solution, and hybridizing the amplified nucleic acid with the probe nucleic acid.

Affymetrix of Santa Clara, Calif., has received US Patent No. 8,323,894, "Methods of analysis of allelic imbalance." A method is claimed for assessing the genomic imprinting status of a cloned embryo. It includes extracting both a genomic DNA sample and an RNA sample from the cloned embryo; simultaneously hybridizing both the genomic DNA sample and the RNA sample to a SNP array; analyzing data from the hybridizing step to generate an imprinted gene expression pattern; comparing the imprinted gene expression pattern to a database of imprinted gene expression patterns from normal embryos at an identical developmental stage; determining the parental origin of at least one gene in the cloned embryo by genotyping both parents and comparing at least one parental genotype to the imprinted gene expression pattern of the cloned embryo; and assessing if the genomic imprinting status of the cloned embryo is normal, where the genomic imprinting status is normal if the imprinted gene expression pattern from the cloned embryo matches the database.

Colorado State University Research Foundation of Fort Collins, Colo., has received US Patent No. 8,323,956, "Distal tip of biosensor transducer comprising enzyme for deamination." The patent claims enzymatic biosensors and methods of producing distal tips for biosensor transducers. According to the patent, these biosensors find use in detecting analytes selected from organic compounds susceptible to dehalogenation, organic compounds susceptible to oxygenation, organic compounds susceptible to deamination, organosulfate compounds susceptible to hydrolysis, and organophosphate compounds susceptible to hydrolysis. Biosensor arrays, methods of detecting and quantifying analytes within a mixture, and devices and methods for delivering reagents to enzymes disposed within the distal tip of a biosensor are also claimed

Luminex of Austin, Texas, has received US Patent No. 8,324,359, "Oxocarbonamide peptide nucleic acids and methods of using same." The patent concerns oxocarbonamide peptide nucleic acids. According to the patent, these OxoPNAs provide increased stability, sensitivity, and specificity as compared to their natural DNA and RNA counterparts. The OxoPNA molecules described may be used in a number of applications, particularly in applications involving hybridization. For example, OxoPNA probes may be employed for the detection and functional analysis of nucleic acid molecules, including miRNAs and other non-coding RNAs, according to the inventors.

Sang Yup Lee and Ki Jun Jeong of Daejeon, Korea, and Nae Choon Yoo, So Young Yoo, Hyun Cheol Chung, Ki Chang Keum, and Won Min Yoo of Seoul, Korea, have received US Patent No. 8,324,363, "Microarray for detection of the deletion of exon 3 of the G-CSF gene." The patent provides a microarray, an antibody, and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region. According to the patent, deletion of the exon 3 region of the G-CSF gene can be used as a cancer biomarker.

Plexera of Woodinville, Wash., has received US Patent No. 8,325,346, "SPR apparatus with a high performance fluid delivery system." A method for operating a surface plasmon resonance test apparatus is claimed. It includes transmitting a first sequence of valve and pump control signals to a fluid delivery system coupled to a flow cell and a microarray; priming the flow cell and microarray with a first solution; receiving images of the microarray; analyzing the images of the microarray to determine if the microarray has been primed; and if priming has occurred, automatically transmitting a second sequence including at least one valve control signal and at least one pump control signal to pump a second fluid through the flow cell and the microarray.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.